Rabbit Polyclonal EGFR phospho Y1068 antibody. Suitable for WB, ICC/IF and reacts with Human samples. Cited in 49 publications. Immunogen corresponding to Synthetic Peptide within Human EGFR phospho Y1068 + Y1068.
Images
Publications
Filter by
- International journal of molecular sciences 24:2023An EGCG Derivative in Combination with Nimotuzumab for the Treatment of Wild-Type EGFR NSCLC.Applications:Unspecified applicationReactive species:Unspecified reactive speciesYanping Huang,Xiangdan Cuan,Weiwei Zhu,Xingying Yang,Yunli Zhao,Jun Sheng,Chengting Zi,Xuanjun WangPubMed 37762316
- International archives of allergy and immunology 184:1010-10212023The ERBB2 Exonic Variant Pro1170Ala Modulates Mitogen-Activated Protein Kinase Signaling Cascades and Associates with Allergic Asthma.Applications:Unspecified applicationReactive species:Unspecified reactive speciesYang Yie Sio,Wei Liang Gan,Wing Shan Ng,Sri Anusha Matta,Yee-How Say,Keng Foo Teh,Yi Ru Wong,Smyrna Moti Rawanan Shah,Kavita Reginald,Fook Tim ChewPubMed 37336194
- Cell reports 39:1109932022KRAS-independent feedback activation of wild-type RAS constrains KRAS inhibitor efficacy.Applications:Unspecified applicationReactive species:Unspecified reactive speciesMeagan B Ryan,Oluwadara Coker,Alexey Sorokin,Katerina Fella,Haley Barnes,Edmond Wong,Preeti Kanikarla,Fengqin Gao,Youyan Zhang,Lian Zhou,Scott Kopetz,Ryan B CorcoranPubMed 35732135
- Cancers 13:2021Ribociclib Induces Broad Chemotherapy Resistance and EGFR Dependency in ESR1 Wildtype and Mutant Breast Cancer.Applications:Unspecified applicationReactive species:Unspecified reactive speciesIsabel Mayayo-Peralta,Beatrice Faggion,Liesbeth Hoekman,Ben Morris,Cor Lieftink,Isabella Goldsbrough,Lakjaya Buluwela,Joseph C Siefert,Harm Post,Maarten Altelaar,Roderick Beijersbergen,Simak Ali,Wilbert Zwart,Stefan PrekovicPubMed 34944934
- Cancers 13:2021Neuropilin-1 Expression Associates with Poor Prognosis in HNSCC and Elicits EGFR Activation upon CDDP-Induced Cytotoxic Stress.Applications:Unspecified applicationReactive species:Unspecified reactive speciesVirginia Napolitano,Daniela Russo,Francesco Morra,Francesco Merolla,Silvia Varricchio,Gennaro Ilardi,Rosa Maria Di Crescenzo,Francesco Martino,Massimo Mascolo,Angela Celetti,Luca Tamagnone,Stefania StaibanoPubMed 34359721
- Scientific reports 11:80162021Chemotherapy confers a conserved secondary tolerance to EGFR inhibition via AXL-mediated signaling bypass.Applications:Unspecified applicationReactive species:Unspecified reactive speciesMark Borris D Aldonza,Roben D Delos Reyes,Young Seo Kim,Jayoung Ku,Ana Melisa Barsallo,Ji-Young Hong,Sang Kook Lee,Han Suk Ryu,YongKeun Park,Je-Yoel Cho,Yoosik KimPubMed 33850249
- Nature communications 12:12612021Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.Applications:Unspecified applicationReactive species:Unspecified reactive speciesHayato Mizuta,Koutaroh Okada,Mitsugu Araki,Jun Adachi,Ai Takemoto,Justyna Kutkowska,Kohei Maruyama,Noriko Yanagitani,Tomoko Oh-Hara,Kana Watanabe,Keiichi Tamai,Luc Friboulet,Kazuhiro Katayama,Biao Ma,Yoko Sasakura,Yukari Sagae,Mutsuko Kukimoto-Niino,Mikako Shirouzu,Satoshi Takagi,Siro Simizu,Makoto Nishio,Yasushi Okuno,Naoya Fujita,Ryohei KatayamaPubMed 33627640
- Clinical cancer research : an official journal of the American Association for Cancer Research 27:3126-31402021Optimized EGFR Blockade Strategies in Addicted Gastroesophageal Adenocarcinomas.Applications:Unspecified applicationReactive species:Unspecified reactive speciesSimona Corso,Filippo Pietrantonio,Maria Apicella,Cristina Migliore,Daniela Conticelli,Annalisa Petrelli,Laura D'Errico,Stefania Durando,Daniel Moya-Rull,Sara E Bellomo,Stefano Ughetto,Maurizio Degiuli,Rossella Reddavid,Uberto Fumagalli,Stefano De Pascale,Giovanni Sgroi,Emanuele Rausa,Gian Luca Baiocchi,Sarah Molfino,Giovanni De Manzoni,Maria Bencivenga,Salvatore Siena,Andrea Sartore-Bianchi,Federica Morano,Salvatore Corallo,Michele Prisciandaro,Maria Di Bartolomeo,Annunziata Gloghini,Silvia Marsoni,Antonino Sottile,Anna Sapino,Caterina Marchiò,Asa Dahle-Smith,Zosia Miedzybrodzka,Jessica Lee,Siraj M Ali,Jeffrey S Ross,Brian M Alexander,Vincent A Miller,Russell Petty,Alexa B Schrock,Silvia GiordanoPubMed 33542076
- Respiratory research 21:2102020FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer.Applications:Unspecified applicationReactive species:Unspecified reactive speciesCuilan Sun et. al.PubMed 32778129
- Mediators of inflammation 2020:10783652020Inhibition of the ROS-EGFR Pathway Mediates the Protective Action of Nox1/4 Inhibitor GKT137831 against Hypertensive Cardiac Hypertrophy via Suppressing Cardiac Inflammation and Activation of Akt and ERK1/2.Applications:Unspecified applicationReactive species:Unspecified reactive speciesSi-Yu Zeng et. al.PubMed 32831633
Key facts
- Isotype
- IgG
- Host species
- Rabbit
- Storage buffer
pH: 7.3
Preservative: 0.05% Sodium azide
Constituents: PBS, 50% Glycerol (glycerin, glycerine), 0.1% BSA- Form
- Liquid
- Clonality
- Polyclonal
Immunogen
- Synthetic Peptide within Human EGFR phospho Y1068 + Y1068. The exact immunogen used to generate this antibody is proprietary information. Database link P00533
Consider this alternative
Reactivity data
Select an application| WB | ICC/IF | |
|---|---|---|
| Human | Tested | Tested |
WB
TestedTested
| Species | Dilution info | Notes |
|---|---|---|
Species Human | Dilution info 1/1000 | Notes - |
ICC/IF
TestedTested
| Species | Dilution info | Notes |
|---|---|---|
Species Human | Dilution info 1/100 | Notes - |
Associated Products
Select an associated product type
6 products for Alternative Product
Target data
Function
Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses (PubMed:10805725, PubMed:27153536, PubMed:2790960, PubMed:35538033). Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF (PubMed:12297049, PubMed:15611079, PubMed:17909029, PubMed:20837704, PubMed:27153536, PubMed:2790960, PubMed:7679104, PubMed:8144591, PubMed:9419975). Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules (PubMed:27153536). May also activate the NF-kappa-B signaling cascade (PubMed:11116146). Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling (PubMed:11602604). Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin (PubMed:11483589). Positively regulates cell migration via interaction with CCDC88A/GIV which retains EGFR at the cell membrane following ligand stimulation, promoting EGFR signaling which triggers cell migration (PubMed:20462955). Plays a role in enhancing learning and memory performance (By similarity). Plays a role in mammalian pain signaling (long-lasting hypersensitivity) (By similarity). Isoform 2 may act as an antagonist of EGF action. (Microbial infection) Acts as a receptor for hepatitis C virus (HCV) in hepatocytes and facilitates its cell entry. Mediates HCV entry by promoting the formation of the CD81-CLDN1 receptor complexes that are essential for HCV entry and by enhancing membrane fusion of cells expressing HCV envelope glycoproteins.
Alternative names
ERBB, ERBB1, HER1, EGFR, Epidermal growth factor receptor, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1
Recommended products
Rabbit Polyclonal EGFR phospho Y1068 antibody. Suitable for WB, ICC/IF and reacts with Human samples. Cited in 49 publications. Immunogen corresponding to Synthetic Peptide within Human EGFR phospho Y1068 + Y1068.
Key facts
- Isotype
- IgG
- Host species
- Rabbit
- Storage buffer
pH: 7.3
Preservative: 0.05% Sodium azide
Constituents: PBS, 50% Glycerol (glycerin, glycerine), 0.1% BSA- Form
- Liquid
- Clonality
- Polyclonal
- Immunogen
- Synthetic Peptide within Human EGFR phospho Y1068 + Y1068. The exact immunogen used to generate this antibody is proprietary information. Database link P00533
- Purification technique
- Affinity purification Immunogen
- Concentration
- Purification notes
The antibody has been negatively preadsorbed using (i) a non phosphopeptide corresponding to the site of phosphorylation to remove antibody that is reactive with non-phosphorylated epidermal growth factor receptor (EGFR), and (ii) a generic tyrosine phosphorylated peptide to remove antibody that is reactive with phosphotyrosine, irrespective of the sequence. The final product is generated by affinity chromatography using an EGFR-derived peptide that is phosphorylated at tyrosine 1068.
Storage
- Shipped at conditions
- Blue Ice
- Appropriate short-term storage conditions
- +4°C
- Appropriate long-term storage conditions
- -20°C
- Aliquoting information
- Upon delivery aliquot
- Storage information
- Avoid freeze / thaw cycle
Notes
Abcam is leading the way to address reproducibility in scientific research with our highly validated recombinant monoclonal and recombinant multiclonal antibodies. Search & select one of Abcam's thousands of recombinant alternatives to eliminate batch-variability and unnecessary animal use.
If you do not find a host species to meet your needs, our catalogue and custom Chimeric range provides scientists the specificity of Abcam's RabMAbs in the species backbone of your choice. Remember to also review our range of edited cell lines, proteins and biochemicals relevant to your target that may help you further your research goals.
Abcam antibodies are extensively validated in a wide range of species and applications, so please check the reagent specifications meet your scientific needs before purchasing. If you have any questions or bespoke requirements, simply visit the Contact Us page to send us an inquiry or contact our Support Team ahead of purchase.
Supplementary info
- This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
EGFR or Epidermal Growth Factor Receptor is a transmembrane glycoprotein that acts as a receptor for members of the epidermal growth factor family. Known alternatively as ErbB1 or HER1 this receptor has an approximate molecular weight of 170 kDa. EGFR is expressed in various cell types notably on epithelial cells and can influence multiple cellular processes through its kinase activity. It participates in the regulation of cell growth multiplication and survival by activating its kinase domain upon ligand binding.
- Biological function summary
The EGFR protein plays an important role in cellular communication and signaling processes. EGFR pairs with other receptor family members to form active dimers or even higher-order complexes which in turn initiate intracellular signaling cascades. Through these complexes EGFR influences many processes including cell differentiation and repair. This function of EGFR makes it an integral part of mammalian biology affecting how cells respond to their environment by mediating changes in gene expression.
- Pathways
EGFR is a central player in the MAPK and PI3K/Akt signaling pathways. Alongside other protein partners like KRAS and PI3 kinase it contributes to transmitting signals from the cell surface to the nucleus affecting gene transcription and cell behavior. These pathways are important for normal cell growth and division and aberrations in these pathways can lead to excessive or insufficient cell proliferation.
- Associated diseases and disorders
EGFR is pertinent to cancer biology including non-small cell lung cancer and glioblastoma where mutations or overexpression of the receptor frequently occur. It connects to proteins such as PTEN and BRAF which influence tumor progression and response to targeted therapies. EGFR's involvement in these disorders highlights its significance as a therapeutic target since it can be manipulated to alter disease progression.
Product promise
Tested
We have tested this species and application combination and it works. It is covered by our product promise.
Expected
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
Predicted
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
Not recommended
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
3 product images
Immunocytochemistry/ Immunofluorescence - Anti-EGFR (phospho Y1068) antibody (ab5644)
Immunofluorescence analysis of A431 (Human epidermoid carcinoma cell line) cells labeling EGFR with ab5644 at 1/100 dilution, followed by Goat anti-rabbit IgG (H+L) Superclonal, Alexa Fluor® 488 conjugate was used as the secondary antibody at 1/2000 dilution (Panel a). Nuclei (Panel b) were stained with SlowFade® Gold Antifade Mountant with DAPI. F-actin (Panel c) was stained with Rhodamine Phalloidin. Panel (d) represents the merged image showing membrane localization. Panel (e) represents cells treated with antagonist, Afatinib (1μM for 6hrs) followed by EGF (200 ng/ml for 10 minutes), showing no Phospho-EGFR staining. Panel (f) shows untreated cells with no signal. Panel (g) represents control cells with no primary antibody to assess background.
The cells (in 70% confluent log phase treated with 200ng/ml of EGF for 10 minutes) were fixed with 4% paraformaldehyde for 10 minutes; permeabilized with 0.1% Triton X-100 for 10 minutes and blocked with 1% BSA for hour at room temperature. The images were captured at 60X magnification.
Western blot - Anti-EGFR (phospho Y1068) antibody (ab5644)
Western blot analysis using ab5644 shows increased expression of proteins phosphorylated at the tyrosine residues in A-431 and A549 cell lines upon EGF treatment and pre-treatment with EGFR-antagonists, Gefitinib and Afatinib. This results in inhibition of Phospho-EGFR in A-431 and A549 cell lines
All lanes: Western blot - Anti-EGFR (phospho Y1068) antibody (ab5644) at 1/1000 dilution
Lane 1: A431 (Human epidermoid carcinoma cell line) whole cell lysate at 30 µg with skimmed milk
Lane 2: A431 whole cell lysate treated with EGF (200 ng/mL for 10 minutes) at 30 µg with skimmed milk
Lane 3: A431 whole cell lysate treated with Gefitinib followed by EGF (1uM for 16 hours, 200 ng/mL for 10 minutes) at 30 µg with skimmed milk
Lane 4: A431 whole cell lysate treated with Afatinib followed by EGF (0.5 uM for 6 hours, 200 ng/mL for 10 minutes) at 30 µg with skimmed milk
Lane 5: A549 (Human lung carcinoma cell line) whole cell lysate at 30 µg with skimmed milk
Lane 6: A549 whole cell lysate treated with EGF (200 ng/mL for 10 minutes) at 30 µg with skimmed milk
Lane 7: A549 whole cell lysate treated with Afatinib followed by EGF (0.5 uM for 6 hours, 200 ng/mL for 10 minutes) at 30 µg with skimmed milk
SecondaryAll lanes: Goat anti-Rabbit IgG Superclonal Secondary Antibody, HRP at 1/4000 dilution
Predicted band size: 134 kDa
This image is courtesy of a customer review submitted by Mr Samir NuseibehWestern blot - Anti-EGFR (phospho Y1068) antibody (ab5644)
All lanes: Western blot - Anti-EGFR (phospho Y1068) antibody (ab5644) at 1/200 dilution
Lane 1: A431 (Human epidermoid carcinoma cell line) whole cell lysate - not treated
Lane 2: A431 whole cell lysate - 100ng/ml EGF for 1 minute
Lane 3: A431 whole cell lysate - 100ng/ml EGF for 2.5 minutes
Lane 4: A431 whole cell lysate - 100ng/ml EGF for 5 minutes
Lane 5: A431 whole cell lysate - 100ng/ml EGF for 10 minutes
Lane 6: A431 whole cell lysate - 100ng/ml EGF for 20 minutes
Lane 7: A431 whole cell lysate - 100ng/ml EGF for 40 minutes
SecondaryAll lanes: HRP conjugated Goat anti-rabbit antibody
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 134 kDa
Exposure time: 2min
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com